We determined the risk factors associated with poor survival in children and adolescents with de novo mature B cell non-Hodgkin lymphoma (B-NHL) who had refractory or relapsed disease during or after the French-American-British mature lymphoma B (FAB/LMB) 96 multi-agent chemotherapy. Among the 1 111 registered on study, 104 patients (9Á4%) had refractory disease or disease relapse after first complete remission. Among these 104 patients, 28 (27%) patients had refractory disease and 76 (73%) had relapsed disease. The estimated 1-and 2-year overall survival (OS) (95% confidence interval) was 31Á5% (23Á3-41Á0%) and 22Á3% (15Á3-31Á4%), respectively. Prognostic analysis of OS using a Cox multivariate model showed that factors independently associated with OS included lactate dehydrogenase ≥2 upper normal limit [hazard ratio (HR) = 2Á86 (1Á57-5Á2), P = 0Á0006]; time to failure (>6 months) [HR = 0Á59 (0Á36-0Á97), P = 0Á038]; and failure in bone marrow [HR = 2Á78 (1Á65-4Á68), P = 0Á0001]. New therapeutic strategies are required to significantly reduce refractory disease and disease relapse in patients with newly diagnosed mature B-NHL and, more importantly, there is a critical need to develop novel retrieval approaches in patients with chemotherapy-resistant disease.
Summary
We determined the risk factors associated with poor survival in children and adolescents with de novo mature B cell non-Hodgkin lymphoma (B-NHL) who had refractory or relapsed disease during or after the French-American-British mature lymphoma B (FAB/LMB) 96 multi-agent chemotherapy. Among the 1 111 registered on study, 104 patients (9Á4%) had refractory disease or disease relapse after first complete remission. Among these 104 patients, 28 (27%) patients had refractory disease and 76 (73%) had relapsed disease. The estimated 1-and 2-year overall survival (OS) (95% confidence interval) was 31Á5% (23Á3-41Á0%) and 22Á3% (15Á3-31Á4%), respectively. Prognostic analysis of OS using a Cox multivariate model showed that factors independently associated with OS included lactate dehydrogenase ≥2 upper normal limit [hazard ratio (HR) = 2Á86 (1Á57-5Á2), P = 0Á0006]; time to failure (>6 months) [HR = 0Á59 (0Á36-0Á97), P = 0Á038]; and failure in bone marrow [HR = 2Á78 (1Á65-4Á68), P = 0Á0001]. New therapeutic strategies are required to significantly reduce refractory disease and disease relapse in patients with newly diagnosed mature B-NHL and, more importantly, there is a critical need to develop novel retrieval approaches in patients with chemotherapy-resistant disease.
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The prognosis for children and adolescents with newly diagnosed mature B cell non-Hodgkin lymphoma (B-NHL) has significantly improved over the past 35 years with the use of short intensive multi-agent chemotherapy. The excellent results of children and adolescents with newly diagnosed B-NHL treated on the French-American-British/mature lymphoma B (FAB/LMB) 96 international trial have previously been reported by our group (Cairo et al, , 2012 Patte et al, 2007; Gerrard et al, 2008 Gerrard et al, , 2013 . The 5-year event-free survival for patients with limited disease (Group A) intermediate risk (Group B) and advanced stage (Group C) was 97 AE 0Á5%, 89 AE 1Á2% and 79 AE 2Á7%, respectively (Cairo et al, , 2012 Patte et al, 2007; Gerrard et al, 2008 Gerrard et al, , 2013 . Overall, the results demonstrated that only two cycles of therapy are required for limited stage disease, therapy could be reduced in intensity for intermediate risk disease but that patients with most advanced disease [bone marrow (BM) AE central nervous system (CNS) disease] require full intensity FAB/LMB 96 therapy (Cairo et al, , 2012 Patte et al, 2007; Gerrard et al, 2008 Gerrard et al, , 2013 .
The factors that were significantly associated with refractory disease or disease relapse during or after FAB/LMB 96 in children and adolescents with mature B-NHL have been reported Patte et al, 2007) . In a multivariate analysis, initial lactate dehydrogenase (LDH) level (<2 vs ≥ 2 times upper limit of normal [ULN]), and primary site (BM+/CNS+ and mediastinal large B cell lymphomas) were significantly associated with an increased risk of refractory disease or disease relapse in children and adolescents treated on FAB/LMB 96 Patte et al, 2007) .
The retrieval and survival rate in children and adolescents who had refractory disease or disease relapse on or after this type of short intensive multi-agent chemotherapy, however, has steadily decreased, presumably secondary to chemoresistant disease (Patte et al, 1986 (Patte et al, , 1991 (Patte et al, , 2001 Bowman et al, 1996; Magrath et al, 1996; Reiter et al, 1999; Atra et al, 2000; Cairo et al, 2002 Cairo et al, , 2003a Cairo et al, ,b, 2007 Cairo et al, , 2012 Spreafico et al, 2002; Woessmann et al, 2005; Gerrard et al, 2008 Gerrard et al, , 2013 Pillon et al, 2011) . Few studies have analysed the outcome of children and adolescents with mature B-NHL who had refractory disease or disease relapse after identical original upfront chemotherapy (Fujita et al, 2008; Anoop et al, 2012 ) Jourdain et al (2015 . recently reported the results of children and adolescents with de novo B-NHL who had disease failure after different LMB regimens in three consecutive Societe Francaise d'Oncologie Pediatrique (SFOP) studies and excluded patients with induction failure or refractory disease. We therefore analysed the impact of possible risk factors that were associated with significantly decreased overall survival (OS) in children and adolescents treated only on one identical upfront treatment protocol, FAB/LMB 96, and who had either refractory or relapsed disease during or after study completion.
Methods
The FAB/LMB 96 was a cooperative international study from over 161 paediatric oncology centres within 3 paediatric oncology cooperative groups: Children's Oncology Group (COG: former Children's Cancer Group institutions in the United States, Canada, and Australia), the United Kingdom Children's Cancer Study Group and SFOP (France and some centres in Belgium and the Netherlands). This protocol was approved by all of the local Institutional Review Boards and written informed consent was obtained from parents/legal guardians and patients if over 18 years of age in accordance with the Declaration of Helsinki. This protocol was registered with clinicaltrials.gov (NCT00002757).
Eligibility for the FAB/LMB96 study
Children and adolescents with newly diagnosed mature B-lineage NHL with either Burkitt lymphoma (BL), diffuse large B-cell lymphoma, or Burkitt-like lymphoma (BLL) according to the Revised European-American Lymphoma classification and World Health Organization Classification were eligible (Murphy, 1980; Harris et al, 1994; Swerdlow et al, 2008) . Staging was performed as previously described by Murphy (1980) . Risk classification was defined as low risk (Group A) with resected stage I and abdominal completely resected Stage II; high risk (Group C) with BM involvement L3 blasts ≥25% and/or CNS disease; intermediate risk (Group B) was all others (Cairo et al, , 2012 Gerrard et al, 2008) . Exclusion criteria included congenital or acquired immunodeficiency, prior malignancy and/or prior chemotherapy Patte et al, 2007; Gerrard et al, 2008) .
Eligibility for the current study
Patients included in the FAB/LMB96 study were primary refractory [never obtained a complete response (CR)] or who relapsed after having achieved CR. Complete remission could be achieved anytime during protocol-derived therapy.
Initial treatment
Patients assigned to Group A, B and C therapy were as previously described (Fig 1) (Cairo et al, , 2012 Patte et al, 2007; Gerrard et al, 2008 Gerrard et al, , 2013 . Patients with a favourable response to COP prophase were randomised to therapy reduction with 50% cyclophosphamide delivered in the second induction cycles and/or the elimination of continuation therapy in a 4-arm stratified randomisation as previously described . Each induction, consolidation and maintenance cycle was approximately 21 days. Patients with less than a 20% response on day 7 of COP and patients with residual disease after cytarabine and methotrexate were given cytabarine with etoposide (CYVE) intensification therapy for two cycles and four cycles of continuation therapy according to Group C therapy (Fig 1) .
Group C. Patients received a 7-day reduction course, COP, as described above . Induction therapy consisted of two cycle of COPADM (with HD-MTX 8 g/ m 2 ). Consolidation consisted of high-dose and continuous CYVE . Patients with CNS disease did not receive cranial radiation but received additional intrathecal therapy as well as an additional HD-MTX course between consolidation courses, as previously described . The first continuation cycle consisted of COPADM, and three additional chemotherapy cycles followed in the standard arm of therapy. Patients with a ≥ 20% response after COP reduction were randomised to a standard arm or a reduced arm with simultaneous reduction in chemotherapy during the consolidation phase (CYVE) and the elimination of the three continuation courses, as previously described (Fig 1) . Each induction, consolidation and maintenance cycle was approximately 21 days, except for the reduction cycle of COP which was only 7 days.
Retrieval therapy
Patients who had primary refractory or relapsed disease on or off this protocol therapy were re-induced and treated according to the discretion of the treating physician and institutional preferences. There was not a uniform approach either to re-induction chemotherapy, use of immunotherapy and/or the use of stem cell transplantation.
Haematopathology
The initial independent and consensus morphology and immunophenotype from diagnostic materials from each case was evaluated by each of the six haematopathologists from the three national cooperative groups to establish a diagnosis using a standard immunophenotyping panel that included the following antibodies: CD20, CD79a, CD3, CD46RO, TDT, CD30and p80, as previously described (Harris et al, 1994; Swerdlow et al, 2008; Cairo et al, 2012) . There was no requirement for central review of patients who had primary refractory or relapsed disease on or off the therapy above.
Statistical methods
Patients were grouped by risk: Group A (limited), Group B (intermediate) and Group C (advanced). The subgroup analysed in this manuscript only consisted of patients who were primary refractory (never obtained a CR) or suffered disease relapse after obtaining a CR. The primary endpoint was OS, which was the time to death from any cause measured from the date of initial treatment failure. We estimated survival probabilities according to the Kaplan-Meier method. The 95% confidence intervals (CI) of survival rates were estimated according to the Rothman method. The prognostic impact on OS of patient characteristics (gender, age), initial disease characteristics (stage, prognosis group, pathological type of B cell lymphoma, primary site, LDH level, BM involvement and CNS involvement) and failure characteristics (time to failure, type of failure, localization of failure, number of sites of failure) was studied by univariate analysis using log-rank test. All factors were also studied by multivariate analysis using Cox model and backward selection based on Wald statistic with removal of variables with P-value >0Á05. Hazard ratios (HR) are presented with their 95% CI. A significant association was considered at P-value ≤0Á05. All reported P-value are two-sided. Analyses were done with SAS version 9.3 (SAS Institute Inc., Cary, NC, USA). (9Á4%) who had primary refractory disease or disease relapse after first CR on or off protocol therapy who were the subject of this analysis. The demographics of the 104 patients who had refractory disease or disease relapse is summarised in Table I . Briefly, 28 (27%) never obtained a CR and were considered primary refractory and 76 (73%) were considered to have relapsed disease after having achieved a CR.
Results

Demographics
Treatment failure (primary refractory or relapsed disease) by initial disease stratification
The percentage of patients based on initial FAB risk classification, St. Jude staging classification and primary disease site was determined. The distribution among patients included: (i) risk classification was 2 (2Á0%) within Group A, 66 (63%) Group B and 36 (35%) Group C patients; (ii) staging classification: I 1 (1%), II 4 (4%), III 58 (56%), IV 12 (12%) and B cell acute lymphoblastic leukaemia (B-ALL) 29 (28%); (iii) primary site: abdominal/retroperitoneal 59 (57%), thorax 16 (15%), head and neck 8 (8%), Burkitt leukaemia 14 (13%), other 7 (7%).
Overall survival
The median follow-up after treatment failure was 4Á4 years. Only three alive patients were followed less than 2 years. Seventy-nine deaths occurred. The probability of 1-and 2-year OS was 31Á5% (95% CI 23Á3-41Á0%) and 23Á3% (95% CI 15Á3-31Á4%), respectively (Fig 2) . Failure characteristics are depicted in Table II . In univariate analysis using the log-rank test, patients with LDH ≥ 2 ULN at diagnosis (P = 0Á004), time to failure ≤6 months (P = 0Á002), failure as primary refractory disease (P = 0Á047) and failure in the BM (P = 0Á003) had significantly worse OS (Table III) .
The probability of 2-year OS in children and adolescents with mature B-NHL who had primary refractory disease or disease relapse during or off FAB/LMB 96 with initial LDH of <2 times ULN versus ≥2 times ULN was 41Á8% vs 14Á9% (P = 0Á004) (Fig 3A) . The probability of 2-year OS in this same population who did not achieve a CR or failure ≤ vs >6 months from diagnosis was 15Á4% vs 34Á5% (P = 0Á002) (Fig 3B) . The probability in this same population who failed in the BM versus no failure in the BM was 11Á5% vs 26%, P = 0Á003 (Fig 4) .
The type of failure (primary refractory disease versus relapse after CR) was strongly associated with the time of failure: in all patients except one who had primary refractory disease, the time of failure was less than 6 months from diagnosis; among patients who relapsed, half of the relapses occurred before 6 months from diagnosis and half after 6 months. Among the patients who relapsed, time to failure was associated with OS. But in patients who had a failure within 6 months from diagnosis, the type of failure (primary refractory disease versus relapse) was not associated with OS.
In the Cox multivariate regression analysis, LDH ≥ 2 times ULN at diagnosis [HR = 2Á86 (1Á57-5Á2), (Table IV) . After taking the time of failure into account, type of failure was not more associated with OS. 
Discussion
This is the largest analysis performed in a large group of children and adolescents with mature B-NHL who had primary refractory disease or disease relapse during or after initial intensive multi-agent chemotherapy treated uniformly in an international trial. Importantly, these patients were initially treated with a risk-stratified uniform multi-institutional and multiple paediatric cooperative group upfront protocol. Despite retrieval therapy at the discretion of the treating physician, the 1-and 2-year OS was only 31Á5% and 22Á3%, respectively. Additionally, these data suggest that patients who had refractory or relapsed disease within 6 months of diagnosis, those with an elevated initial LDH level ≥2 times ULN at diagnosis and/or those who failed in the BM have a significantly decreased OS. While initial LDH levels have been identified previously as an independent risk factor for disease failure (Reiter et al, 1999; Patte et al, 2001 Patte et al, , 2007  HR, hazard ratio; LDH, lactate dehydrogenase; NL, normal limit. Cairo et al, 2002 Cairo et al, , 2003b Cairo et al, , 2012 Pillon et al, 2004; Gerrard et al, 2008) , this finding is similar to that of Jourdain et al (2015) who also demonstrated that initial LDH is a significant risk factor for decreased OS in a population who fail on or following initial upfront LMB chemotherapy in three consecutive SFOP studies. The Children's Cancer Group previously analysed the OS in 212 children with disseminated large cell lymphoma and focused on the subgroup who relapsed (Cairo et al, 2002) . This retrospective analysis demonstrated a 1-year OS of approximately 31 AE 4Á7% (Cairo et al, 2002) . Similarly, 470 children and adolescents with disseminated BL, BLL or Burkitt leukaemia were analysed over a 20-year period (Bowman et al, 1996) . In patients with BL/BLL or B-ALL who relapsed, the 1-year OS was 16% (Bowman et al, 1996) . These results, from an analysis of children and adolescents treated from 1977-1994, are similar to the results of the current study (Bowman et al, 1996; Cairo et al, 2002) . However, the Children's Cancer Group did not specifically address the prognostic factors associated with OS in those patients who had refractory disease or disease relapse during or after initial mature B-NHL therapy in either of these reports.
FAB risk group classification (Group A vs B vs C) clearly identifies patients with an increased risk of refractory or relapsed disease with the percentage of patients experiencing an adverse event (toxic death, secondary malignancy, refractory or relapsed disease) being 1%, 11% and 21%, respectively. Age was historically considered as a risk factor because adolescents were considered to be at higher risk for failure (Cairo et al, 2003a; Hochberg et al, 2009 ). In our analysis, adolescent age at initial presentation did not reach significance as an independent risk factor for OS after refractory disease or disease relapse (Cairo et al, 2012) . Although male gender is predominant in children and adolescent mature B-NHL, there was no significant decreased risk of OS in males versus females in these patients who had refractory disease or disease relapse during or after initial FAB/LMB 96 therapy. Furthermore, the decreased OS in patients with Stage IV disease as a risk factor did not reach significance in the Cox multivariate regression analysis.
One of the most important findings in this study was that the interval from initial diagnosis to refractory disease or disease relapse (less than 6 months) was significantly associated with a decreased OS following initial treatment on FAB/LMB 96. This is similar to the results of the Jourdain et al (2015) The COG demonstrated that in patients with refractory or relapsed lymphoma who achieved a CR/partial response (PR) after reinduction and then underwent cyclophosphamide, carmustine, and etoposide conditioning and autologous stem cell transplantation, those patients whose remission was < 12 vs ≥ 12 months duration had a significantly decreased OS (Harris et al, 2011) . Early haematological relapse appears to denote more resistant disease and commonly results in a significant decrease in OS in children with mature B-NHL as well as those with ALL (Perkins et al, 2003) .
Clearly there is a need to reduce the incidence of refractory or relapsed disease during upfront therapy (especially in group C patients) and to develop more novel and targeted retrieval regimens to circumvent drug resistance in all children and adolescents who have refractory disease or disease relapse on upfront contemporary multi-agent chemotherapy regimens. CD20, the target of rituximab, is expressed in more than 98% of all children and adolescents with mature B-NHL (Perkins et al, 2003) . The safety of adding rituximab to children and adolescents with newly diagnosed Stage III/IV mature B-NHL with the B4 and C1 treatment arms of FAB/LMB 96 has been piloted (Shiramizu et al, 2011; Goldman et al, 2013 Goldman et al, , 2014 . Reporting for the Berlin-Frankfurt-Munster group Meinhardt et al (2010) , also included the safety and efficacy of rituximab with upfront multi-agent chemotherapy. The benefit of adding rituximab to FAB/LMB 96 therapy in children and adolescents with newly diagnosed high-risk mature B-cell lymphoma/leukaemia was recently reported in the randomised prospective international Inter-B-NHL study (Minard-Colin et al, 2015) . However, the OS in children and adolescents with B-NHL treated with a rituximab-containing chemoimmunotherapy regimen are not significantly better in patients who have disease failure compared to those with chemotherapy only, such as illustrated in this study (Hochberg et al, 2009; Meinhardt et al, 2010) .
Numerous regimens, usually incorporating a platinum compound, have been reported to show efficacy in patients with mature B-NHL after disease failure Gentet et al (1990) ; Philip et al (1993) have demonstrated the success of CYVE as salvage treatment in refractory mature B-NHL and disease failure. Kobrinsky et al (2001) , has reported on the use of dexamethasone, etoposide, cisplatin, cytarabine and L-asparaginase in recurrent/refractory childhood NHL. This regimen however, utilises agents that are currently used today in high-risk mature B-NHL patients as upfront therapy, including corticosteroids, cytarabine and etoposide. Kung et al (1999) and Cairo et al (2001) have reported on the use of ifosfamide, carboplatin and etoposide for recurrent/refractory childhood NHL. Most recently Griffin et al (2009) , reported a 60% overall response rate (CR + PR) in children and adolescents with mature B-NHL following combination chemoimmunotherapy with rituximab and ICE. Children and adolescents with refractory disease and/or disease relapse mature B-NHL who achieve a CR or PR after reinduction are candidates for a stem cell transplant consolidation. When autologous stem cells can be harvested and are clear of tumour, consolidation with a myeloablative autologous stem cell transplant may be considered (Kobrinsky et al, 2001; Bradley & Cairo, 2008; Gross et al, 2010; Harris et al, 2011) . Alternatively, a full intensity or reduced intensity conditioning followed by an allogeneic stem cell transplantation may also be considered in patients with stable or CR/PR after reinduction therapy (Gross et al, 2010; Satwani et al, 2015) .
This retrospective analysis has some limitations. This was a retrospective analysis and was not specifically designed nor powered to address specific risk or prognostic factors that were present at the time of refractory disease or disease relapse and risk of overall long-term OS. However, there are no known genetic and/or molecular factors at disease failure in this population that predict OS after retrieval therapy. Moreover, we do not have information on LDH level at refractory disease or disease relapse, or retrieval or reinduction regimens, nor whether patients received an autologous vs. allogeneic stem cell transplant as consolidation. The majority of these patients did not however receive rituximab in their reinduction therapy as rituximab was not available for children during this time period. Similarly, whether autologous or allogeneic stem cell transplantation was utilised in patients obtaining a CR or PR after retrieval therapy, the results do not indicate an advantage to either stem cell transplantation approach (Pillon et al, 2011) . However, the results (OS) were comparable across three paediatric cooperative groups (COG vs SFOP vs UKCCSG) (Table IV) . Most importantly, all patients (N = 1,111) were treated on the same uniform upfront protocol (FAB/LMB 96), as this represents the largest experience ever reported in children and adolescents with newly diagnosed mature B-NHL.
In summary, these results have demonstrated that initial LDH levels ≥2 times ULN, refractory disease or disease relapse less than 6 months from diagnosis and/or failure in the BM are each independently associated with a significant decrease in OS in children and adolescents with mature B-NHL who had refractory or relapsed disease during or after contemporary multi-agent chemotherapy, such as FAB/ LMB 96. These results provide critical information to health care providers and families about the chance of survival for children and adolescents with mature B-NHL with refractory or relapsed disease. Future strategies should continue to identify risk factors associated with primary refractory disease or disease relapse, such as tumour cytogenetics or minimal disseminated disease at diagnosis and minimal residual disease following induction therapy, and subsequently design new therapeutic strategies to reduce refractory disease or disease relapse during upfront therapy (Mussolin et al, 2007; Poirel et al, 2009; Shiramizu et al, 2011 Shiramizu et al, , 2015 Satwani et al, 2015) . Alternative new retrieval approaches include the identification of new targets, use of new monoclonal antibodies or conjugated antibodies, and novel approaches of cellular and stem cell therapy (Cooney-Qualter et al, 2007; Barth et al, 2013; Awasthi et al, 2015; Shiramizu et al, 2015) . Furthermore, targeting more specific molecular or cellular pathways in children and adolescents with mature B cell lymphoma should be studied in a cooperative setting to improve the long term OS in this poor risk group of patients (Pinkerton et al, 2016; Lee et al, 2017 
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